×
×

Ras family mutations (KRAS & NRAS)

Ras family mutations (KRAS & NRAS)

Recent reserach indicates that the absence of activating mutations in KRAS and NRAS genes (exons 2, 3 and 4 for each gene) is necessary for the treatment of metastatic colorectal cancer with anti-EGFR antibodies.

Reference:

Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek J, Reese D, Patterson SD. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013 Apr 1;19(7):1902-12.

Category
Department
Medical specialty
Required sample
Quantity
3-5 sections
Turn around time
Genes
Technology
Next Generation Sequencing